Zacks: Analysts Expect Natera Inc (NTRA) Will Post Quarterly Sales of $62.87 Million

Share on StockTwits

Analysts predict that Natera Inc (NASDAQ:NTRA) will announce $62.87 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Natera’s earnings. The highest sales estimate is $65.68 million and the lowest is $61.59 million. Natera posted sales of $53.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 16.9%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 12th.

According to Zacks, analysts expect that Natera will report full year sales of $253.49 million for the current financial year, with estimates ranging from $252.28 million to $256.37 million. For the next fiscal year, analysts anticipate that the company will report sales of $294.57 million, with estimates ranging from $275.00 million to $326.29 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Natera.

NTRA has been the topic of a number of research reports. ValuEngine downgraded Natera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 9th. Cowen reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Natera in a research note on Friday, November 9th. Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. Finally, BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Friday, December 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $28.25.

NASDAQ:NTRA opened at $15.22 on Tuesday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44. Natera has a 1 year low of $8.60 and a 1 year high of $29.62. The company has a market capitalization of $911.90 million, a price-to-earnings ratio of -6.34 and a beta of 1.79.

Several institutional investors have recently made changes to their positions in the company. Prescott Group Capital Management L.L.C. boosted its holdings in shares of Natera by 18.6% in the 4th quarter. Prescott Group Capital Management L.L.C. now owns 147,628 shares of the medical research company’s stock worth $2,061,000 after purchasing an additional 23,200 shares during the period. First Trust Advisors LP purchased a new position in shares of Natera in the 4th quarter worth approximately $2,813,000. Jennison Associates LLC boosted its holdings in shares of Natera by 1.8% in the 4th quarter. Jennison Associates LLC now owns 3,706,873 shares of the medical research company’s stock worth $51,748,000 after purchasing an additional 65,025 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Natera in the 4th quarter worth approximately $1,311,000. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of Natera by 3.2% in the 4th quarter. Essex Investment Management Co. LLC now owns 126,506 shares of the medical research company’s stock worth $1,766,000 after purchasing an additional 3,912 shares during the period. Hedge funds and other institutional investors own 87.50% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: What Does Beta Mean In Stock Selection

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reliance Steel & Aluminum Co  Shares Sold by Jensen Investment Management Inc.
Reliance Steel & Aluminum Co Shares Sold by Jensen Investment Management Inc.
Ecolab Inc.  is Jensen Investment Management Inc.’s 6th Largest Position
Ecolab Inc. is Jensen Investment Management Inc.’s 6th Largest Position
Vanguard Dividend Appreciation ETF  Shares Sold by Macroview Investment Management LLC
Vanguard Dividend Appreciation ETF Shares Sold by Macroview Investment Management LLC
Macroview Investment Management LLC Acquires New Position in iShares Core MSCI Europe ETF
Macroview Investment Management LLC Acquires New Position in iShares Core MSCI Europe ETF
DasCoin  Price Up 0.9% This Week
DasCoin Price Up 0.9% This Week
Mossland Reaches Market Capitalization of $6.05 Million
Mossland Reaches Market Capitalization of $6.05 Million


Leave a Reply

© 2006-2019 Ticker Report